New patent expiration for APGDI drug MYRBETRIQ
Annual Drug Patent Expirations for MYRBETRIQ Myrbetriq is a drug marketed by Apgdi and is included in two NDAs. It […]
Patent Expiration
New patent expiration for Otsuka drug ABILIFY MYCITE KIT
Annual Drug Patent Expirations for ABILIFY+MYCITE+KIT Abilify Mycite Kit is a drug marketed by Otsuka and is included in one
New patent expiration for Otsuka drug ABILIFY MYCITE KIT Read Post »
New patent expiration for Otsuka Pharm drug ABILIFY MAINTENA KIT
Annual Drug Patent Expirations for ABILIFY+MAINTENA+KIT Abilify Maintena Kit is a drug marketed by Otsuka Pharm Co Ltd and is
New patent expiration for Otsuka Pharm drug ABILIFY MAINTENA KIT Read Post »
New patent expiration for Otsuka drug ABILIFY
Annual Drug Patent Expirations for ABILIFY Abilify is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is
New patent expiration for Chiesi drug BETHKIS
Annual Drug Patent Expirations for BETHKIS Bethkis is a drug marketed by Chiesi and is included in one NDA. It
Drug Patent Expirations for the Week of September 18, 2022
BETHKIS (tobramycin) Chiesi Patent: 6,987,094 Expiration: Sep 22, 2022 See More … For more information on how DrugPatentWatch can help
Drug Patent Expirations for the Week of September 18, 2022 Read Post »
New patent expiration for Novo Nordisk drug VAGIFEM
Annual Drug Patent Expirations for VAGIFEM Vagifem is a drug marketed by Novo Nordisk Inc and is included in one
New patent expiration for Novo Nordisk drug VAGIFEM Read Post »
Drug Patent Expirations for the Week of September 11, 2022
BREO ELLIPTA (fluticasone furoate; vilanterol trifenatate) Glaxo grp ltd Patent: 7,776,895 Expiration: Sep 11, 2022 See More … For more
Drug Patent Expirations for the Week of September 11, 2022 Read Post »
New patent expiration for Novartis drug CIPRODEX
Annual Drug Patent Expirations for CIPRODEX Ciprodex is a drug marketed by Novartis and is included in one NDA. It
New patent expiration for Novartis drug CIPRODEX Read Post »
